Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03291990 · ClinicalTrials.gov registry record · Early Phase 1
5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme
A Early Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT03291990 is a Early Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 3 participants.
The verdict
NCT03291990, a Early Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This investigation is not only to develop an improved radiation/temozolomide approach, but also develop a regimen with potential to form the basis of better combined therapy with immune based treatments.
Interventions
- DRUG Temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-10-18 |
| Est. Completion | 2020-08-19 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03291990
The ClinicalTrials.gov registry entry for NCT03291990 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Temozolomide is the first listed.
NCT03291990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03291990 about?
NCT03291990 is a clinical study titled "5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme". This investigation is not only to develop an improved radiation/temozolomide approach, but also develop a regimen with potential to form the basis of better combined therapy with immune based treatments.
What is the current status of trial NCT03291990?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2017-10-18. Estimated completion is 2020-08-19.
What interventions are being tested in trial NCT03291990?
The interventions under investigation include: Temozolomide (DRUG).
Who is sponsoring clinical trial NCT03291990?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.